Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus fingolimod in pediatric relapsing-remitting multiple sclerosis
NL-OMON56373Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ocrelizumab arm with Fingolimod arm (2 arms). Primary endpoint: Protocol-defined annualized relapse rate during the double-blind period. Planned start Sep 2021; status: withdrawn.
02
Drugs
ocrelizumabfingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON56373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56373.